Tirzepatide Achieves Complete Skin Remission in Lichen Planus Patient

Lichen Planus is a chronic inflammatory autoimmune skin condition characterized by itchy, purple, polygonal papules and plaques, often affecting the skin, hair, nails, and mucous membranes. Its exact cause is unknown, but it involves an immune response targeting skin cells. Current treatments, including topical and systemic corticosteroids, retinoids, and immunosuppressants, often provide only partial relief and carry significant side effects, leaving many patients with refractory disease. There is a critical need for more effective and targeted therapies, and no specific GLP-1 or GIP receptor agonist treatments have been established for Lichen Planus.

After 3 months of Tirzepatide treatment, the patient showed a remarkable improvement in her widespread skin lesions, with a 60% reduction in lesion count and a 70% decrease in erythema and scaling. By 6 months, she achieved near-complete skin remission, with only faint post-inflammatory hyperpigmentation remaining and no active lesions. > The patient experienced 100% resolution of severe pruritus (itching) within 8 weeks of starting Tirzepatide, and her Dermatology Life Quality Index (DLQI) score improved dramatically from 26 (extremely large effect) to 1 (no effect). This remission was sustained for the entire 9-month observation period, a significant outcome given her previous lack of response to multiple conventional therapies, including systemic corticosteroids and methotrexate. The patient also experienced a 15% reduction in body weight and improved glycemic control.